HighTower Advisors
MRNA icon

HighTower Advisors’s Moderna MRNA Stock Holding History

HighTower Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$4 – 3902
2025
Q1 		$4 Sell
100
-100
-50% -$3.55K ﹤0.01% 3720
2024
Q4 		$595 Buy
+200
New +$9.56K ﹤0.01% 3725
2024
Q3 		– Sell
-1,600
Closed -$50.7K – 3885
2024
Q2 		$50.7K Sell
1,600
-200
-11% -$25.3K ﹤0.01% 3307
2024
Q1 		$23.2K Buy
+1,800
New +$181K ﹤0.01% 3339
2023
Q2 		– Sell
-100
Closed -$4.19K – 3589
2023
Q1 		$4.19K Buy
+100
New +$16.5K ﹤0.01% 3242
2022
Q3 		– Sell
-100
Closed -$1K – 3301
2022
Q2 		$1K Buy
100
+96
+2,400% +$13.7K ﹤0.01% 3193
2022
Q1 		$22K Buy
+4
New +$673 ﹤0.01% 3156
2021
Q3 		– Sell
-500
Closed -$9K – 3340
2021
Q2 		$9K Buy
+500
New +$89.4K ﹤0.01% 3005
2020
Q4 		– Sell
-300
Closed -$6K – 2746
2020
Q3 		$6K Sell
300
-300
-50% -$20.9K ﹤0.01% 2453
2020
Q2 		$2K Buy
600
+200
+50% +$11K ﹤0.01% 2382
2020
Q1 		$2K Buy
+400
New +$9.2K ﹤0.01% 2179

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

HighTower Advisors's MRNA Position: Q2 2026 in Review

HighTower Advisors increased its Moderna (MRNA) stake by 22% in Q2 2026, buying an estimated $292K and bringing the position to 31,822 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1698.

HighTower Advisors first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $19.4M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • HighTower Advisors held 31,822 shares of Moderna worth $2.23M as of Q2 2026.
  • HighTower Advisors bought 5,647 Moderna shares in Q2 2026, an estimated $292K.
  • Moderna made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1698 holding.
  • HighTower Advisors first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • HighTower Advisors's Moderna position peaked at $19.4M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.